Suven Life Sciences Ltd

- There is no mention of any current or future fundraising through debt or equity in the provided transcript. - The management did not indicate plans for raising capital via equity or debt during this period. - CAPEX plans totaling Rs.100 crore over 15 months are funded internally for facility upgrades rather than through external fundraising. - The focus appears to be on organic growth through clinical trial progress and CRAMS business expansion. - No guidance or discussion was provided regarding capital raising activities in the call.

- Suven Life Sciences plans a significant capital expenditure (CAPEX) of Rs.100 crore over a 15-month period starting FY17. - This investment is for the construction of an additional block and upgradation of facilities at the CRAMS business site in Pashamylaram. - The CAPEX includes both recurring/replacement CAPEX of Rs.15 crore to Rs.20 crore annually and the new CAPEX for expansion. - Initial FY17 CAPEX is expected to be around Rs.20 crore as part of regular CAPEX. - For FY18, the company initially considered Rs.50 crore for facility upgradation but expanded it to Rs.100 crore by adding a new block. - This investment aims to enhance containment facilities and handle new chemical entities, supporting future growth in CRAMS. - No other specific strategic investments or out-licensing deals currently announced; focus remains on facility upgrades and clinical trial progression.

- Core CRAMS business expected to grow by 10% to 15% annually, as mentioned by Venkat Jasti. - Specialty chemicals segment is mature with flat or marginal growth expected (±5%). - Repeat business orders estimated around Rs. 40-50 crore in the next fiscal years (FY18-FY19). - No significant top-line growth currently; future growth depends on molecules in the pipeline advancing to next stages. - Clinical trial progress, especially on SUVN-502, is crucial for unlocking potential out-licensing deals and revenue growth. - New CAPEX of Rs. 100 crore planned for CRAMS facility enhancement to support future business opportunities. - Expected EBITDA margins sustained at around 30%, supporting profitability growth. - Specialty chemical revenues likely to remain around Rs. 200 crore range, with minor year-on-year variances.

- Suven Life Sciences expects core CRAMS business growth of about 10% to 15% annually, reflecting mature yet steady expansion. - EBITDA margins are anticipated to remain strong around 30% for the next one to two quarters, driven by better product mix and difficult-to-make projects commanding higher prices. - Specialty chemicals segment is expected to be flat or fluctuate within a ±5% range, indicating limited growth potential. - Commercial repeat orders estimated between Rs. 40 crore to Rs. 50 crore for the next two years, providing steady revenue support. - Pipeline advancement: Positive results from NCE Phase-2 trials (e.g., SUVN-502) could catalyze top-line and bottom-line growth, but no definitive timeline or guarantees yet. - Overall, profits and EPS growth hinge on successful clinical trial outcomes and pipeline progress; management is optimistic but cautious.

- As of the call, there are no pending orders for the three commercialized molecules. - The company expects repeat business/orders in the range of Rs. 40 crore to Rs. 50 crore for the next two years. - For the specialty chemicals segment, the revenue is expected to remain flat with possible variation of +/- 5%. - In the CRAMS business, the company anticipates growth of around 10% to 15%. - Rs. 30 crore worth of molecule repeat orders were expected in the current quarter; Rs. 15 crore executed so far. - Anticipated orders of Rs. 70 crore to Rs. 80 crore expected in the fourth quarter, partly seasonal. - No new significant out-licensing deals or orders are currently confirmed. - The company is focusing more on the CRAMS business for top-line and margin growth.